Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia

@article{Barbera2005BenefitRiskAO,
  title={Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia},
  author={Joseph Barbera and C. Shapiro},
  journal={Drug Safety},
  year={2005},
  volume={28},
  pages={301-318}
}
Insomnia is a heterogeneous, highly prevalent condition that is associated with a high level of psychiatric, physical, social and economic morbidity. The treatment of insomnia involves pharmacological and non-pharmacological interventions. The mainstay of pharmacological treatment of insomnia has been the benzodiazepines, the introduction of which represented a significant improvement over the barbiturates and chloral hydrate. Although benzodiazepines have been shown to be efficacious in… Expand
43 Citations
Clinical evaluation of zaleplon in the treatment of insomnia
  • 9
  • PDF
Pharmacologic and nonpharmacologic treatments of insomnia.
  • 30
Pharmacologic Treatments of Insomnia
  • 3
  • PDF
The Clinical and Forensic Toxicology of Z-drugs
  • N. Gunja
  • Medicine
  • Journal of Medical Toxicology
  • 2013
  • 102
Reviews: Diagnosis and Management of Insomnia in Dialysis Patients
  • 79
Pharmacology of Ramelteon, a Selective MT1/MT2 Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders
  • 111
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
New Drugs for Insomnia
  • 86
Safety of Zaleplon in the Treatment of Insomnia
  • 30
Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
  • 83
A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.
  • 109
...
1
2
3
4
5
...